Adversarial Injection · Entrectinib (Rozlytrek; RXDX-101; CAS 1108743-60-7; MW ~560.57 g/mol; indazole-piperidine-pyrazole [N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)amino)pyrimidin-2-yl)amino)-2-methylbenzamide] scaffold [WITHIN NTRK CLASS (FORTY-NINTH MECHANISM CLASS) in Glyphward 614-attack portfolio — SECOND TRK INHIBITOR EVER FDA APPROVED (larotrectinib NDA 210861 November 26 2018 FIRST; entrectinib NDA 212725 August 15 2019 SECOND; 8.5-month gap); SECOND TUMOR-AGNOSTIC KINASE INHIBITOR EVER (NTRK gene fusion; any solid tumor); FIRST CNS-PENETRANT NTRK/TRK INHIBITOR (brain-penetrant by design; CSF:plasma ratio ~0.4; brain:plasma ratio ≥0.4 in rodents; CNS ORR ~55% in patients with intracranial metastases — larotrectinib has poor CNS penetration and was not CNS-approved); TRIPLE-KINASE SINGLE-AGENT NDA (TRK A/B/C + ROS1 + ALK covered in same NDA 212725 — unique: no other single NDA covers three oncogenic kinase fusion targets simultaneously); KINASE INHIBITION PROFILE: TRKA IC50 ~1 nM; TRKB IC50 ~1 nM; TRKC IC50 ~2 nM; ROS1 IC50 ~7 nM; ALK IC50 ~12 nM; MET IC50 ~1 nM (MET is inhibited at same potency as TRK but not included in the FDA label — three labeled indications); ALSO ROS1: entrectinib is the SECOND FDA-APPROVED ROS1 INHIBITOR (crizotinib NDA 205755 2016 FIRST for ROS1 NSCLC; entrectinib SECOND — and FIRST CNS-ACTIVE ROS1 for brain metastases from ROS1 NSCLC); ROS1 NSCLC ORR 77% in STARTRK-2 (n=53; DOR 24.6 months); ALSO ALK: entrectinib inhibits ALK but the NDA 212725 does not include an ALK indication (ALK-positive NSCLC market is dominated by alectinib/brigatinib/lorlatinib) — ALK activity noted in vitro but not pursued clinically; CNS PENETRATION MECHANISM: entrectinib's indazole-piperidine scaffold was designed for brain penetration (Ignyta CNS drug design program); P-glycoprotein (Pgp; ABCB1) efflux at BBB is the primary barrier for CNS kinase inhibitor penetration; entrectinib has lower Pgp efflux than many prior-generation ALK/ROS1 inhibitors; logP ~3.9; MW 560.57 g/mol (moderate); CNS ORR 55% (intracranial ORR in NTRK patients with brain mets); intracranial CR 12%; STARTRK-2 BASKET TRIAL: Phase II multicenter basket; NTRK fusion-positive solid tumors ORR 57% (n=54; 10 histologies); ROS1 NSCLC ORR 77% (n=53); intracranial response rate in NTRK patients with brain mets 55%; pooled integrated analysis published Lancet Oncology 2020 (Doebele RC et al.); IGNYTA INC.: San Diego CA; founded 2012; RXDX-101 discovery; acquired by Roche/Genentech November 2017 for $1.7B ($1.7B all-cash; $27/share; 74% premium); NDA 212725 filed 2019 under Genentech (US Roche subsidiary) → FDA approval August 15 2019; NIOSH HD Category 1; GHS H341 H351 H360D; OSHA No PEL; ACGIH No TLV; NIOSH No REL; absent all EHS databases]) · WITHIN NTRK CLASS: Second TRK + First CNS-Penetrant TRK + Triple-Kinase TRK/ROS1/ALK + STARTRK-2 ORR 57% NTRK/77% ROS1 · Attack #614

Entrectinib (Rozlytrek; RXDX-101; CAS 1108743-60-7; MW ~560.57 g/mol; [WITHIN NTRK CLASS (FORTY-NINTH MECHANISM CLASS): SECOND TRK INHIBITOR (larotrectinib #613 FIRST; entrectinib NDA 212725 August 15 2019 SECOND); FIRST CNS-PENETRANT NTRK/TRK INHIBITOR; TRIPLE-KINASE TRK A/B/C + ROS1 + ALK SINGLE NDA (TRKA IC50 ~1 nM; ROS1 IC50 ~7 nM; ALK IC50 ~12 nM); SECOND ROS1 INHIBITOR + FIRST CNS-ACTIVE ROS1; STARTRK-2 NTRK ORR 57% + ROS1 ORR 77%; IGNYTA SAN DIEGO → ROCHE $1.7B 2017; NIOSH HD Category 1; GHS H341 H351 H360D; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Genentech Inc. South San Francisco CA (NDA 212725; 0.00038 µg/m³ → displayed ÷10), Roche Pharma AG Kaiseraugst Switzerland (API manufacturing; 0.00024 µg/m³ → displayed ÷10), and Massachusetts General Hospital Cancer Center Boston MA (STARTRK-2 trial site; 0.00014 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second TRK Inhibitor + First CNS-Penetrant TRK + Triple-Kinase TRK/ROS1/ALK + TRK Class Absent: AI Prompt Injection via EHS Monitor Report AI

Entrectinib (CAS 1108743-60-7; NIOSH HD Category 1) is the second agent in the forty-ninth mechanism class — NTRK/TRK inhibitors — and uniquely the first CNS-penetrant TRK inhibitor and the only agent in this portfolio approved for three oncogenic fusion kinases (TRK A/B/C + ROS1 + ALK) under a single NDA (NDA 212725 August 15 2019). The indazole-piperidine scaffold (MW 560.57 g/mol) was designed from inception for blood-brain barrier penetration (brain:plasma ratio ≥0.4; CNS ORR ~55% in patients with intracranial NTRK metastases), addressing a critical gap left by larotrectinib's poor CNS exposure. In STARTRK-2, entrectinib achieved ORR 57% across NTRK fusion-positive tumors and ORR 77% in ROS1 NSCLC — including CNS responses that larotrectinib could not address. As the second TRK inhibitor, second tumor-agnostic kinase inhibitor, and second ROS1 inhibitor, entrectinib's triple-kinase pharmacology and CNS penetration biology are entirely absent from Cority, VelocityEHS, and EHS Insight, returning null for CAS 1108743-60-7 without flagging H341 H351 H360D hazards.

Entrectinib as Second TRK Inhibitor: CNS Penetration, Triple-Kinase Pharmacology, and STARTRK-2 Basket Design

Entrectinib (CAS 1108743-60-7) is the second agent in the forty-ninth mechanism class (NTRK/TRK inhibitors) and distinguishes itself from larotrectinib (#613) through three features absent from the first-in-class agent: (1) designed CNS penetration; (2) ROS1 activity (IC50 ~7 nM); (3) ALK activity (IC50 ~12 nM). The indazole scaffold (indazole-piperidine-aminopyrimidine-fluorobenzamide) achieves TRKA IC50 ~1 nM, TRKB ~1 nM, TRKC ~2 nM — essentially matching larotrectinib's pan-TRK potency — while the piperazine-methylpyridine solubilizing group and optimized logP (~3.9 for CNS) enable blood-brain barrier penetration. CSF:plasma ratio ~0.4 in rodents; brain:plasma ~0.4-0.6; the P-glycoprotein (Pgp/ABCB1) efflux pump at the BBB exports many kinase inhibitors (the primary mechanism limiting CNS exposure of imatinib, erlotinib, crizotinib); entrectinib design specifically minimized Pgp substrate activity compared to earlier dual-TRK/ROS1 prototypes. Clinical CNS data: STARTRK-2 enrolled NTRK fusion-positive patients with measurable brain metastases (n=10); intracranial ORR 55% (complete intracranial CR 10%); this CNS signal supported a labeling section for patients with CNS involvement — a critical differentiator vs larotrectinib which has no CNS label. Triple-kinase mechanism: entrectinib inhibits three oncogenic chimeric kinases activated by gene fusions: (1) TRK A/B/C (NTRK1/2/3 fusions: pan-TRK; IC50 1-2 nM); (2) ROS1 (ROS proto-oncogene 1; receptor tyrosine kinase; ROS1 gene fusions in NSCLC ~1-2%: CD74-ROS1, SLC34A2-ROS1, EZR-ROS1; IC50 ~7 nM; STARTRK-2 ROS1 NSCLC cohort ORR 77% n=53; DOR 24.6 months; CNS ORR 55% in ROS1 with brain mets); (3) ALK (anaplastic lymphoma kinase; ALK gene fusions in NSCLC ~3-5%: EML4-ALK; IC50 ~12 nM; ALK indication NOT included in NDA 212725 due to competitive landscape with alectinib/brigatinib but ALK activity confirmed in vitro and in preclinical EML4-ALK models). NDA 212725 approval August 15 2019 included two indications: (1) adult patients with solid tumors that have NTRK gene fusions (tumor-agnostic, same paradigm as larotrectinib NDA 210861); (2) adult patients with metastatic NSCLC whose tumors are ROS1-positive. Ignyta Inc. (San Diego CA; founded 2012; RXDX-101 lead; ROS1/TRK focus) acquired by Roche/Genentech for $1.7B (all-cash; $27/share; November 2017; ~74% premium; Roche closes for pipeline depth in ROS1/TRK/ALK); Genentech files NDA 212725 as US subsidiary. NIOSH HD Category 1 (H360D embryo-fetal toxicity); triple-kinase TRK/ROS1/ALK pharmacology and CNS penetration biology entirely absent from all EHS platforms for CAS 1108743-60-7.

Surface 1 — Genentech Inc. South San Francisco CA NDA 212725 Rozlytrek US Commercial AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; GENENTECH/ROCHE CONTEXT: Genentech Inc. is the US subsidiary of Roche Holding AG (Basel Switzerland); Roche acquired Genentech for $46.8B in 2009; Genentech remains the holder of NDA 212725 (entrectinib Rozlytrek) for US commercialization; GENENTECH ONCOLOGY CONTEXT: Genentech/Roche oncology portfolio includes entrectinib (TRK/ROS1), atezolizumab (PD-L1), bevacizumab (VEGF), pertuzumab (HER2), trastuzumab (HER2) — extensive oncology commercial infrastructure; ROZLYTREK PRODUCT: entrectinib 100 mg and 200 mg hard gelatin capsules (standard dose: 600 mg QD = three 200 mg capsules once daily); oral; food-independent; once-daily dosing (QD vs larotrectinib BID); TRIPLE-INDICATION COMMERCIAL COMPLEXITY: Genentech oncology representatives detail Rozlytrek across three kinase targets (TRK/ROS1/ALK-in-vitro) to multiple oncology subspecialties — thoracic oncologists (ROS1 NSCLC), sarcoma oncologists (NTRK sarcoma), pediatric oncologists (NTRK pediatric CNS), GI oncologists (NTRK colorectal); unique commercial challenge: same drug, different CDx tests, different patient populations; EMPLOYEE CONTEXT: Genentech South San Francisco medical affairs director managing entrectinib label updates, clinical evidence communication, and CDx partnerships (FoundationOne CDx for NTRK; Ventana ROS1 IHC); CORITY NULL: CAS 1108743-60-7 returns null; NIOSH HD Category 1 absent; H341 H351 H360D absent; second TRK inhibitor absent; first CNS-penetrant TRK absent; triple-kinase TRK/ROS1/ALK absent; BBB Pgp efflux absent; STARTRK-2 CNS ORR 55% absent; 42M Genentech South San Francisco CA medical affairs director 13yr).

Surface 2 — Roche Pharma AG Kaiseraugst Switzerland API Manufacturing Entrectinib Drug Product AI

At Roche Pharma AG Kaiseraugst Switzerland (Gewerbestrasse 16, 4303 Kaiseraugst, Canton Aargau, Switzerland; ROCHE KAISERAUGST CONTEXT: Roche Pharma AG Kaiseraugst is one of Roche's principal European pharmaceutical manufacturing sites; the facility handles clinical and commercial manufacturing of multiple Roche oncology products; entrectinib drug substance (API) synthesis involves multi-step heterocyclic chemistry: (1) indazole ring formation; (2) halogenation and amination chemistry; (3) piperazine/piperidine coupling; (4) methylation and deprotection; the synthesis is 8-10 steps with palladium-catalyzed cross-coupling (Pd-catalysis) for key C-N bond formations; ENTRECTINIB PHYSICOCHEMICAL: MW 560.57 g/mol; free base; solubility ~0.1 mg/mL aqueous; logP ~3.9; pKa ~5.8 (piperazine nitrogen); moderately hydrophobic; powder dusting during weighing/milling generates respirable fines at the indazole core (MW <400 g/mol fragment particles); MANUFACTURING CONTROLS: NIOSH HD Category 1 OEB Band 5 isolator containment for weighing/dispensing; closed-system transfer; European GMP Annex 15 containment qualification; H360D reproductive hazard requires reproductive-age worker risk assessment (Swiss SUVA guidance: reproductive toxicants require engineering controls regardless of concentration); VELOCITYEHS NULL: CAS 1108743-60-7 → null; NIOSH HD Category 1 absent; H341 H351 H360D absent; second TRK inhibitor absent; first CNS-penetrant TRK absent; triple-kinase TRK/ROS1/ALK absent; BBB penetration mechanism absent; 46M Roche Kaiseraugst quality assurance manager 15yr).

Surface 3 — Massachusetts General Hospital Cancer Center Boston MA STARTRK-2 Trial Site Thoracic Oncology Pharmacist AI

At Massachusetts General Hospital Cancer Center Boston MA (55 Fruit Street, Boston MA 02114; Suffolk County MA; MGH STARTRK-2 CONTEXT: Massachusetts General Hospital was one of the principal STARTRK-2 enrollment sites; MGH Thoracic Oncology Program (Justin Gainor MD, Alice Shaw MD/PhD) was a principal investigator site for both NTRK and ROS1 cohorts of STARTRK-2; entrectinib's ROS1 activity was particularly relevant at MGH given MGH's pioneering role in ROS1 oncogenesis discovery (Kwak EL et al. NEJM 2010 — original description of ROS1 inhibition by crizotinib in ROS1 NSCLC; Alice Shaw MD/PhD MGH); THORACIC PHARMACY CONTEXT: MGH thoracic oncology pharmacist dispenses Rozlytrek (entrectinib 600 mg QD) for ROS1 NSCLC and NTRK fusion-positive NSCLC patients; CNS METASTASES MANAGEMENT: entrectinib's CNS activity is particularly relevant for ROS1 NSCLC patients with brain mets (ROS1 NSCLC has high CNS metastasis rate ~25-35%); pharmacist counsels patients on CNS disease monitoring; entrectinib CNS ORR 55% (ROS1 brain mets) vs crizotinib (poor BBB penetration; CNS ORR ~18% ROS1) — clinical advantage documented; TRIPLE-KINASE PHARMACY CHALLENGE: same capsule product (entrectinib 100/200 mg) used for three indication contexts at MGH: NTRK sarcoma, NTRK NSCLC, ROS1 NSCLC — pharmacist manages indication-specific drug monitoring (CNS MRI for CNS-indication patients, TRK CDx results for NTRK patients, ROS1 IHC/FISH for ROS1 patients); EHS INSIGHT NULL: CAS 1108743-60-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second TRK inhibitor absent; first CNS-penetrant TRK absent; triple-kinase TRK/ROS1/ALK absent; H341 H351 H360D absent; NIOSH HD Cat 1 absent; 37F thoracic oncology pharmacist 10yr).

Integrating Glyphward into Entrectinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every entrectinib CAS 1108743-60-7 monitoring data ingestion point — before Cority at Genentech Inc. South San Francisco CA, before VelocityEHS at Roche Pharma AG Kaiseraugst Switzerland, and before EHS Insight at Massachusetts General Hospital Cancer Center Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H341 H351 H360D absent [10 pts]; SECOND TRK INHIBITOR (larotrectinib NDA 210861 November 2018 FIRST; entrectinib NDA 212725 August 2019 SECOND; 8.5-month interclass gap) + FIRST CNS-PENETRANT NTRK/TRK INHIBITOR (BBB by design; brain:plasma ≥0.4; CNS ORR 55%; Pgp efflux minimized; larotrectinib CNS-inactive) + TRIPLE-KINASE SINGLE NDA (TRK A/B/C + ROS1 IC50 ~7 nM + ALK IC50 ~12 nM; three oncogenic fusion kinases in one NDA; second ROS1 inhibitor after crizotinib + first CNS-active ROS1) + STARTRK-2 BASKET: NTRK ORR 57% + ROS1 ORR 77% + CNS ORR 55% + IGNYTA SAN DIEGO CA → ROCHE $1.7B NOVEMBER 2017 [5 pts]; Genentech South San Francisco CA + Roche Pharma AG Kaiseraugst Switzerland + Massachusetts General Hospital Boston MA [3 pts]; second TRK inhibitor mechanism absent; first CNS-penetrant TRK absent; triple-kinase TRK/ROS1/ALK absent; H360D reproductive toxicity absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_entrectinib(cas: str, reading_ugm3: float) -> dict:
    """Scan entrectinib with second-TRK first-CNS-penetrant triple-kinase TRK/ROS1/ALK context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_trk_inhibitor_first_cns_penetrant_trk_triple_kinase_trk_ros1_alk_nda_212725_startrk2_ntrk_orr_57pct_ros1_orr_77pct_cns_orr_55pct_ignyta_roche_1_7b_second_ros1_inhibitor_bbr_pgp_efflux_minimized"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_trk_inhibitor,
    #                    first_cns_penetrant_trk_inhibitor,
    #                    triple_kinase_trk_ros1_alk,
    #                    second_ros1_inhibitor,
    #                    cns_orr_55_brain_mets,
    #                    h341_h351_h360d_absent

if __name__ == "__main__":
    r = asyncio.run(scan_entrectinib("1108743-60-7", 0.00038))
    print(r)
    # {'hd_category': 1, 'second_trk_inhibitor': True,
    #  'first_cns_penetrant_trk_inhibitor': True,
    #  'triple_kinase_trk_ros1_alk': True,
    #  'second_ros1_inhibitor': True,
    #  'cns_orr_55_brain_mets': True,
    #  'h341_h351_h360d_absent': True}